GenScript Targeted LNP: Precision Delivery for Enhanced Therapeutics
GenScript provides targeted lipid nanoparticle (LNP) formulation services for precision RNA delivery applications, including immune cell engineering, in vivo CAR-T, gene editing, and therapeutic development. By combining optimized LNP formulations with ligand-mediated targeting strategies, the GenScript platform is designed to improve delivery efficiency, targeting specificity, and translational potential for advanced RNA ther…
Place your order directly with the manufacturer.
GenScript offers targeted lipid nanoparticle (LNP) solutions to support efficient and specific RNA delivery for advanced therapeutic research. Backed by extensive expertise in mRNA synthesis and LNP formulation, the GenScript platform enables the development of customized delivery strategies for a variety of cell and tissue targets, helping researchers accelerate programs from early-stage discovery to translational research.
The GenScript targeted LNP platform includes antibody-conjugated, peptide-conjugated, and other ligand-decorated LNP systems designed for applications such as immune cell engineering, in vivo CAR-T development, gene editing, mRNA therapeutics, vaccine research, and targeted RNA delivery studies. In addition to a portfolio of optimized formulations, GenScript also provides customized formulation development and optimization services tailored to specific payloads and research needs.
With integrated capabilities spanning payload preparation, LNP formulation, characterization, and analytical testing, GenScript delivers end-to-end support to help researchers streamline RNA delivery development and improve experimental outcomes.
